Search hospitals > South Carolina > Greenville
Greenville Cancer Treatment Center
Claim this profileGreenville, South Carolina 29605
Global Leader in Cancer
Global Leader in Leukemia
Conducts research for Tumors
Conducts research for Lymphoma
Conducts research for Recurrence
163 reported clinical trials
5 medical researchers
Summary
Greenville Cancer Treatment Center is a medical facility located in Greenville, South Carolina. This center is recognized for care of Cancer, Leukemia, Tumors, Lymphoma, Recurrence and other specialties. Greenville Cancer Treatment Center is involved with conducting 163 clinical trials across 310 conditions. There are 5 research doctors associated with this hospital, such as Ki Chung, MD, Tarek M. Sabagh, Michael Guy, MD, and Jhansi L. Koduri.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Leukemia
Global LeaderStage II
Stage I
CD7 positive
Top PIs
Ki Chung, MDPrisma Health Cancer Institute - Eastside5 years of reported clinical research
Expert in Cancer
Expert in Tumors
95 reported clinical trials
196 drugs studied
Tarek M. SabaghMiami Valley Hospital South4 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
68 reported clinical trials
124 drugs studied
Michael Guy, MDMiami Valley Hospital South1 year of reported clinical research
Studies Cancer
Studies Ovarian Cancer
17 reported clinical trials
45 drugs studied
Jhansi L. KoduriMiami Valley Hospital South1 year of reported clinical research
Studies Breast Cancer
Studies Cancer
7 reported clinical trials
21 drugs studied
Clinical Trials running at Greenville Cancer Treatment Center
Breast Cancer
Lung Cancer
Cancer
Melanoma
Gastric Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Esophageal Cancer
Gastroesophageal Junction Adenocarcinoma
Esophageal Adenocarcinoma
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Greenville Cancer Treatment Center?
Greenville Cancer Treatment Center is a medical facility located in Greenville, South Carolina. This center is recognized for care of Cancer, Leukemia, Tumors, Lymphoma, Recurrence and other specialties. Greenville Cancer Treatment Center is involved with conducting 163 clinical trials across 310 conditions. There are 5 research doctors associated with this hospital, such as Ki Chung, MD, Tarek M. Sabagh, Michael Guy, MD, and Jhansi L. Koduri.